Healthon: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://healthon.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.

1. 1

   ““Same active ingredient as Wegovy and Ozempic.””

2. 2

   ““Clinically proven weight loss””

3. 3

   ““The active ingredient in our formula is FDA-approved….””

4. 4

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

healthon.com returned a live storefront when we checked in August 2026, offering doctor-led weight-loss plans with an advertised starting price and separate semaglutide and tirzepatide products. We did not review every page on the site.

This is the letter to read if you have ever been reassured by the phrase "FDA-approved active ingredient." It is a real distinction — the molecule genuinely is the one in an approved product — and it is also the single most effective way to make a cheaper vial feel equivalent to a costlier one. FDA cited it because approval attaches to a finished product: a specific formulation, made under a specific application, at a specific strength. The ingredient passing that test tells you nothing about the vial around it. Notice what the letter does not say: it makes no finding about how this company's product was made or whether it works. It is about the sentence, not the syringe. If a price looks lower than a brand's, the honest comparison is compounded-versus-brand, not approved-versus-approved.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Healthon failed to respond.